| Company Name: | Johnson & Johnson | | Ticker Symbol: | JNJ | | | WWW Address: | www.jnj.com |
| CEO: | Alex Gorsky | | No. of Employees: | 127,600 |
| Common Issue Type: | CS | | Business Description: | Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the health care field.
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Major [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 84.86 |  0.0 | - | - | | 84.96 | 83.08 | 1400 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 238,362.1 | 2,808.9 | 0.55 | 3.86 | 2.40 | 23.1 | 3.1 | 89.99 - 65.82 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 84.91 | $ | | PE Ratio - LTM | 23.1 | |
| Market Capitalisation | 238,362.1 | mil |
| Latest Shares Outstanding | 2,808.9 | mil |
| Earnings pS (EPS) | 3.86 | $ |
| Dividend pS (DPS) | 2.40 | ¢ |
| Dividend Yield | 3.1 | % |
| Dividend Payout Ratio | 62 | % |
| Revenue per Employee | 526,834 | $ |
| Effective Tax Rate | 23.7 | % |
| Float | 2,790.7 | mil |
| Float as % of Shares Outstanding | 99.8 | % |
| Foreign Sales | 37,394 | mil |
| Domestic Sales | 29,830 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 30.70 | % |
| Research & Devlopment (R&D) as % of Revenue | 12.00 | % |
| Gross Profit Margin | 73.2 | % |
| EBITDA Margin | 30.5 | % |
| Pre-Tax Profit Margin | 18.9 | % |
| Assets Turnover | 0.6 | % |
| Return on Assets (ROA) | 8.3 | % |
| Return on Equity (ROE) | 15.1 | % |
| Return on Capital Invested (ROCI) | 12.9 | % |
| Current Ratio | 2.1 | |
| Leverage Ratio (Assets/Equity) | 1.8 | |
| Interest Cover | 26.5 | |
| Total Debt/Equity (Gearing Ratio) | 0.24 | |
| LT Debt/Total Capital | 15.0 | % |
| Working Capital pS | 8.79 | $ |
| Cash pS | 5.29 | $ |
| Book-Value pS | 23.80 | $ |
| Tangible Book-Value pS | 5.87 | $ |
| Cash Flow pS | 4.99 | $ |
| Free Cash Flow pS | 0.16 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 3.57 | |
| Price/Tangible Book Ratio | 14.46 | |
| Price/Cash Flow | 17.0 | |
| Price/Free Cash Flow | 528.8 | |
| P/E as % of Industry Group | 86.0 | % |
| P/E as % of Sector Segment | 125.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Dividend Declared Date | 04/24/2013 |
| Dividend Ex-Date | 05/22/2013 |
| Dividend Record Date | 05/27/2013 |
| Dividend Pay Date | 06/10/2013 |
| Dividend Amount | 660 |
| Type of Payment | Cash Payment |
| Dividend Rate | 2.64 |
| Current Dividend Yield | 3.1 |
| 5-Y Average Dividend Yield | 3.3 |
| Payout Ratio | 62.0 |
| 5-Y Average Payout Ratio | 51.0 |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.0 | 100 | 98,804 | 343,352 |
| 4 Weeks | 89.99 | 82.65 | 88.09 | -3.6 | 98 | 101,588 | 1,828,580 |
| 13 Weeks | 89.99 | 78.50 | 79.19 | 7.2 | 102 | 98,024 | 6,077,518 |
| 26 Weeks | 89.99 | 69.18 | 70.69 | 20.1 | 104 | 99,891 | 12,286,577 |
| 52 Weeks | 89.99 | 65.82 | 66.01 | 28.6 | 106 | 108,965 | 27,023,263 |
| YTD | 89.99 | 70.30 | - | 21.1 | 106 | 97,900 | 11,062,741 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 84.68 | 84.45 | 85.06 | 77.93 | 75.40 | 0.55 | 0.38 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 1.44 | 54.2 | 2.90 |
| Income | -3.10 | 25.4 | -8.15 |
| Dividend | 7.42 | 98.8 | 6.38 |
| Capital Spending | 8.51 | NA | 18.86 |
| R&D | 0.52 | NA | 4.32 |
| Normalized Inc. | -2.44 | NA | -6.75 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 8.5 | 8.5 | 3.4 |
| Earnings % | -10.6 | -10.6 | 8.7 |
| EPS % | -13.5 | -13.5 | 10.6 |
| EPS $ | -0.19 | -0.19 | 0.37 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 18.01 |
| Current Ratio | 1.9 |
| Quick Ratio (Acid Test) | 1.3 |
| Liquidity Ratio (Cash) | 0.87 |
| Receivables Turnover | 6.1 |
| Average Collection Period | 59 |
| Working Capital/Equity | 33.7 |
| Working Capital pS | 7.82 |
| Cash-Flow pS | 5.07 |
| Free Cash-Flow pS | 0.49 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 3.93 |
| Financial Leverage Ratio (Assets/Equity) | 1.9 |
| Debt Ratio | 46.6 |
| Total Debt/Equity (Gearing Ratio) | 0.25 |
| LT Debt/Equity | 0.18 |
| LT Debt/Capital Invested | 42.3 |
| LT Debt/Total Liabilities | 20.3 |
| Interest Cover | 26.9 |
| Interest/Capital Invested | 0.55 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 14.36 |
| Tobin's Q Ratio | 1.97 |
| Current P/E Ratio - LTM | 23.10 |
| Enterprise Value (EV)/EBITDA | 13.23 |
| Enterprise Value (EV)/Free Cash Flow | 208.99 |
| Dividend Yield | 3.1 |
| Price/Tangible Book Ratio - LTM | 14.46 |
| Price/Book Ratio - LTM | 3.57 |
| Price/Cash Flow Ratio | 17.0 |
| Price/Free Cash Flow Ratio - LTM | 528.8 |
| Price/Sales Ratio | 3.48 |
| P/E Ratio (1 month ago) - LTM | 23.4 |
| P/E Ratio (26 weeks ago) - LTM | 23.2 |
| P/E Ratio (52 weeks ago) - LTM | 18.1 |
| 5-Y High P/E Ratio | 19.5 |
| 5-Y Low P/E Ratio | 10.5 |
| 5-Y Average P/E Ratio | 15.5 |
| Current P/E Ratio as % of 5-Y Average P/E | 149 |
| P/E as % of Industry Group | 86.0 |
| P/E as % of Sector Segment | 125.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 21.4 |
| PER SHARE FIGURES |
| LT Debt pS | 4.11 |
| Current Liabilities pS | 8.68 |
| Tangible Book Value pS - LTM | 5.87 |
| Book Value pS - LTM | 23.80 |
| Capital Invested pS | 27.17 |
| Cash pS - LTM | 5.29 |
| Cash Flow pS - LTM | 4.99 |
| Free Cash Flow pS - LTM | 0.16 |
| Earnings pS (EPS) | 3.86 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 2.03 |
| Free Cash Flow Margin 5YEAR AVG | 7.26 |
| Net Profit Margin | 15.6 |
| Net Profit Margin - 5YEAR AVRG. | 18.4 |
| Equity Productivity | 1.04 |
| Return on Equity (ROE) | 16.2 |
| Return on Equity (ROE) - 5YEAR AVRG. | 21.6 |
| Capital Invested Productivity | 0.88 |
| Return on Capital Invested (ROCI) | 13.8 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 18.3 |
| Assets Productivity | 0.60 |
| Return on Assets (ROA) | 8.7 |
| Return on Assets (ROA) - 5YEAR AVRG. | 11.3 |
| Gross Profit Margin | 73.2 |
| Gross Profit Margin - 5YEAR AVRG. | 74.2 |
| EBITDA Margin - LTM | 30.5 |
| EBIT Margin - LTM | 19.7 |
| Pre-Tax Profit Margin | 20.5 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 23.7 |
| Effective Tax Rate | 23.7 |
| Effective Tax Rate - 5YEAR AVRG. | 22.5 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 199 |
| Revenue per Employee | 526,834 |
| Net Income per Employee | 82,398 |
| Average Collection Period | 61 |
| Receivables Turnover | 6.1 |
| Day's Inventory Turnover Ratio | 138 |
| Inventory Turnover | 2.6 |
| Inventory/Sales | 11.1 |
| Accounts Payble/Sales | 15.63 |
| Assets/Revenue | 1.67 |
| Net Working Capital Turnover | 3.08 |
| Fixed Assets Turnover | 0.89 |
| Total Assets Turnover | 0.6 |
| Revenue per $ Cash | 4.51 |
| Revenue per $ Plant | 4.18 |
| Revenue per $ Common Equity | 1.04 |
| Revenue per $ Capital Invested | 0.88 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 31.0 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 32.1 |
| Research & Devlopment (R&D) as % of Revenue | 11.4 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 11.4 |
|
|  
| | |  |  | |
| |
